Decoding The First-Ever MDCG Guidelines For Annex XVI Products!


Posted January 18, 2024 by ChangJin

The newly proposed MDCG guidelines are a valuable resource for manufacturers (of products without an intended medical purpose), notified bodies, and stakeholders navigating the intricate landscape of medical device regulatory standards.

 
Scope:
The newly proposed MDCG guidelines are a valuable resource for manufacturers (of products without an intended medical purpose), notified bodies, and stakeholders navigating the intricate landscape of medical device regulatory standards. A comprehensive review of these guidelines is crucial to maintain the safety and efficacy of medical devices in the market.

On 14th December 2023, the Medical Device Coordination Group (MDCG) has released two new documents: MDCG 2023-5 (Guidance on qualification and classification of Annex XVI products) & MDCG 2023-6 (Guidance on demonstration of equivalence for Annex XVI products)

What Is Annex XVI of EU MDR?
Annex XVI of EU MDR 2017/745 outlines six categories of products which are governed by EU MDR even though they lack an intended medical purpose. The European Commission determined that products falling within these categories, for which manufacturers claim only aesthetic or non-medical purposes but exhibit similarities to medical devices in terms of functionality and risk profile, should be covered by the EU MDR.

Requirements Of Annex XVI Products:

Both the new guidelines are a must-read for the manufacturers of device that fall under Annex XVI medical devices (products without an intended medical purpose).

New MDCG 2023-5 guideline:

• Guidance on qualification and classification of Annex XVI products – A guide for manufacturers and notified bodies.
• This guidance document provides elements useful for the qualification of a product as a product without an intended medical purpose listed in Annex XVI to the MDR. It also provides explanations and examples for the application of certain classification rules to products without an intended medical purpose.
• This guidance document should be used in conjunction with the MDCG 2021-24 on classification of medical devices and take into consideration Commission Implementing Regulation (EU) 2022/2347 on reclassification.

In addition, the guidance is particularly focused on dual-purpose devices, addressing the complexities of classifying products that serve both medical and non-medical purposes. It also offers practical advice on interpreting relevant terms and concepts, aiding manufacturers and notified bodies in ensuring regulatory compliance within the EU.

Additional Crucial Points of MDCG 2023-5:

• Accessories for non-medical products aren’t specifically mentioned in Article 2 of the MDR. However, the guidance clarifies that they fall under regulation if they match the description in Annex XVI and fit the definition of a regulated product in the CS. If an accessory can be used with a product, it can be sold as part of that product. If it can be used independently, it can be considered a stand-alone product.

• Dual-purpose devices, claiming both medical and non-medical purposes, must meet the stringent requirements of both the CS (Common Specifications) and the MDR, particularly regarding risk. If simultaneous dual-purpose use is not achieved, apply MDR and CS requirements separately, but consider combining certain measures as they may impact both intended purposes.

• In the case of Multi-Purpose Products, the product may share characteristics with multiple groups of Annex XVI. Ideally, each product should belong to only one of the six groups. But, if the product falls under more than two or more groups, the cumulative requirements of all applicable requirements in the CS shall apply.

These would be classified as Class III, Rule 8 according to MDCG 2023-5. These fall under section 2 of Annex XVI of EU MDR 2017/745, which states products intended to be totally or partially introduced in the human body through surgically invasive means for the purpose of modifying the anatomy or fixation of body parts.

New MDCG 2023-6 guideline:

• Guidance on demonstration of equivalence for Annex XVI products – A guide for manufacturers and notified bodies.
• This MDCG guidance covers the demonstration of equivalence, based on data pertaining to an already existing device, for the purpose of CE-marking under the MDR and is applicable to products without an intended medical purpose listed in the Annex XVI of MDR and covered by the CS (Common Specifications). For dual-purpose devices, which are devices with a medical and a non-medical intended purpose, this guidance applies only to the non-medical intended purpose.

• This guidance document should be used in conjunction with MDCG 2020-5 on equivalence.

In conclusion, when embracing these guidelines, it is crucial to understand the guiding principles and consider the similarities with medical devices.

https://mavenprofserv.com/cracking-mdcg-your-annex-xvi-roadmap/

References:

[1] EU MDR 2017/745
[2] EU 2022/2346
[3] EU 2022/2347
[4] MDCG 2023-5: Guidance on qualification and classification of Annex XVI products
[5] MDCG 2021-24: Guidance on classification of medical devices
[6] Figure-1
[7] MDCG 2023-6: Guidance on demonstration of equivalence for Annex XVI products
[8] MDCG 2020-5: Clinical Evaluation – Equivalence
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Chang Jin Maven
Country Hong Kong SAR
Categories Business , Health , Medical
Tags mdcg , mdcgguidelines
Last Updated January 18, 2024